STAT Plus: FDA rejects Intarcia’s diabetes implant for a second time

For the second time, the Food and Drug Administration rejected an Intarcia Therapeutics implant aimed at treating type 2 diabetes, the company said Tuesday.

“We are extremely disappointed,” Intarcia spokesperson Sunny Uberoi told STAT in a statement. “We remain steadfast in our belief that [the implant] holds important potential as a new treatment option for people managing type 2 diabetes.”

Continue to STAT Plus to read the full story…

Read Original Article: STAT Plus: FDA rejects Intarcia’s diabetes implant for a second time »